In the world of pharmaceutical warnings, a Boxed Warning — colloquially called a “Black Box Warning” — is the FDA’s highest alert level short of pulling a drug from the market entirely. It appears in a prominent black-bordered box at the top of a drug’s prescribing information. It means: this drug can cause serious harm if used incorrectly, and we want to make absolutely sure you know that before you open the tube.
Testosterone gels have had a Boxed Warning for secondary transfer since at least 2009. That is not a minor footnote. That is the FDA printing, in large black type, a warning that a drug intended to be applied to a man’s body can cause measurable physiological harm to people who never asked for testosterone and never knew they were being exposed to it.
Understanding why gels transfer — and why this matters — requires a brief trip into the chemistry of how these products work.
How Testosterone Gels Actually Work
Testosterone gels are hydroalcoholic preparations: a mixture of testosterone dissolved in an alcohol-based carrier with various excipients to aid skin penetration. The gel is applied to the skin (typically shoulders, upper arms, or abdomen), and the alcohol evaporates within minutes, leaving a thin film of testosterone on the skin surface.
Here is the critical point: the testosterone does not all absorb immediately. Gels are designed for slow, sustained absorption over the full 24-hour dosing period. A significant portion of the active drug sits on the skin surface throughout the day, especially in the hours immediately after application, before it has gradually diffused through the stratum corneum into circulation.
That surface residue is active. It is transferable. It will move onto the skin of anyone who comes into physical contact with the treated area.
The prescribing information for AndroGel 1.62%, for example, explicitly states that patients should wash their hands immediately after application, cover the treated area with clothing once dry, and avoid swimming or bathing for at least one hour after application. Patients are instructed to keep treated areas covered when physical contact with others is likely.
These instructions represent the gel’s primary defense against transfer: behavioral. Wash your hands. Put on a shirt. Remember not to hug your kid right after applying testosterone to your upper arm.
What Happens When Transfer Occurs
The documented cases of secondary exposure are not hypothetical. They are in the medical literature, and they are affecting children.
The FDA’s 2009 Boxed Warning update was prompted by reports of secondary testosterone exposure in children whose fathers or caregivers used testosterone gels. The presentations included:
- Premature pubic hair development in children under 24 months of age
- Advanced bone age
- Aggressive behavior
- Enlarged penis or clitoris
- Accelerated growth beyond expected patterns
These are the clinical signs of precocious puberty — a condition triggered by androgenic exposure at an age when testosterone should not yet be acting on the body. The FDA documented at least 20 post-marketing reports of virilization in children associated with transdermal testosterone transfer in its 2009 action, though the true number of exposed children was certainly higher.
Women, particularly pregnant women, are also at risk from secondary transfer. Testosterone exposure in pregnancy carries documented risks of fetal harm, including virilization of female fetuses. Women experiencing secondary exposure to gel-treated partners can develop acne, changes in body or facial hair, clitoral enlargement, and menstrual irregularities.
Why Behavioral Mitigation Is Structurally Insufficient
The pharmaceutical and regulatory solution to gel transfer has been, fundamentally, to tell patients to be more careful. Wash hands. Cover skin. Don’t let children touch treated areas. This is a reasonable response given the available tools at the time these products were developed.
But it puts an enormous behavioral burden on the patient.
Consider the daily operational reality: a man applies testosterone gel to his shoulders every morning. He must:
- Apply the gel and wait for it to dry (typically 5 to 10 minutes)
- Wash his hands thoroughly before touching anything
- Put on a shirt immediately and keep that area covered
- Avoid swimming or showering for at least an hour
- Ensure that family members, including curious toddlers and affectionate partners, do not come into skin-to-skin contact with treated areas
On a quiet Sunday morning, this is manageable. Over the course of weeks, months, and years, with a household that includes young children who climb on their parents without announcing their intentions, it is asking a lot. The failure mode is not laziness — it is the ordinary, unpredictable nature of life in a family.
Surveys of men on testosterone gel therapy have documented concerns about family exposure as a significant driver of anxiety and non-adherence. A meaningful subset of men who would otherwise be candidates for TRT decline gel therapy specifically because they live with partners, children, or elderly relatives who should not be exposed to testosterone.
The Axiron Applicator: An Attempt at Engineering
The testosterone transdermal solution Axiron (applied to underarms via a dedicated applicator) represented one attempt to address this problem through design rather than purely behavioral modification. By using an applicator instead of bare hands, and by targeting the underarm area — which tends to be more consistently covered — Axiron modestly reduced the contact transfer risk.
The Shoskes et al. 2016 review noted that Axiron’s applicator design was “novel in its use of an applicator which prevents users from touching the solution, potentially decreasing transmission risk to others unlike testosterone gels.” That is damning with faint praise. “Potentially decreasing” is not the same as “effectively eliminating.”
The fundamental problem remained: testosterone sitting on skin surface is available for transfer until it is fully absorbed. An applicator reduces the surface area of exposed hands. It does not solve the underlying chemistry.
The Clinical Consequence
The transfer issue has not killed gel adoption — AndroGel remains one of the top-selling testosterone products in the United States. But it has meaningfully narrowed the patient population for whom gels are clinically appropriate. Physicians routinely consider household composition when prescribing transdermal TRT. A 45-year-old man with no children and a partner who has been fully counseled is a different prescription decision than a 35-year-old father of a toddler.
That friction has clinical consequences. It means some men who need testosterone therapy aren’t getting it, or are choosing suboptimal delivery methods to avoid transfer risk. The problem is structural, not behavioral. Structural problems need structural solutions.
What would a structural solution look like? A formulation that dries rapidly, minimizes surface residue, delivers a precise dose, and dramatically reduces the transferable fraction on the skin surface.
That sounds like a spray.
Next up: Post 3 examines exactly how metered-dose transdermal spray technology differs from gels — not just in form, but in the pharmacokinetics, the surface residue profile, and the clinical data behind it.
